Lorlatinib for Previously Treated ALK-positive Advanced NSCLC: Updated Efficacy and Safety Data from a Phase 2 Study in China

被引：0

作者：

Lu, S. ^{[1
]}

Zhou, Q. ^{[2
]}

Liu, X. ^{[3
]}

He, S. ^{[4
]}

Zhao, H. ^{[4
]}

Li, H. ^{[4
]}

Wu, Y. ^{[2
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[2] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China

[3] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China

[4] Pfizer Inc, Shanghai, Peoples R China

来源：

关键词：

non-small cell lung cancer; lorlatinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA06.11

引用

页码：S121 / S121

页数：1